Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial.

Abstract

8507 Background: AlloSCT gives encouraging results in pts with relapsed PTCL. We did the AATT (Autologous or Allogeneic Transplantation in T-Cell Lymphoma) study in newly diagnosed PTCL and present results of an interim analysis leading to termination of the trial. Methods: We compared alloSCT with autoSCT in younger pts with PTCL. Pts were randomized after enrolment. Treatment was four courses of CHOEP-14. Pts achieving CR/ PR/ SD proceeded to DHAP and stem cell collection in pts randomized to autoSCT or without suitable (HLA 10/10) donor. BEAM high-dose therapy and autoSCT or myeloablative conditioning and alloSCT followed within 4-6 weeks. Results: 58/104 pts were eligible: median age was 50 years, 64% of pts were male. 11/30 pts randomized to autoSCT did not proceed to transplantation because of progressive disease / no response (n=8), infection (n=1) or change of histology (n=2). 13/28 pts (46%) randomized to alloSCT received it. Fifteen pts were not allografted due to progressive disease (n=10) or l...